 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...27282930313233343536373839 |
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 12, 2012
P3, N=567, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: RAPID 2: A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 7, 2012
P3, N=857, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Jan 29, 2012
P3, N=880, Active, not recruiting, Sponsor: UCB, Inc.
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Jan 25, 2012
P3, N=880, Active, not recruiting, Sponsor: UCB Pharma SA
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Dec 26, 2011
P4, N=892, Active, not recruiting, Sponsor: UCB Pharma SA
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial initiation date, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 14, 2011
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Initiation date: Sep 2011 --> Dec 2011
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 13, 2011
P3, N=100, Active, not recruiting, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Initiation date: Sep 2011 --> Dec 2011 Recruiting --> Active, not recruiting
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 13, 2011
P3, N=127, Completed, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: NORD-STAR: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (clinicaltrials.gov) - Dec 12, 2011
P4, N=800, Recruiting, Sponsor: Karolinska Institutet
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial termination: SWIFT: A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Nov 17, 2011
P3, N=3, Terminated, Sponsor: UCB, Inc.
Suspended --> Terminated; Termination of study due to low enrollment. There were no safety issues.
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: SWIFT: A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Nov 17, 2011
P3, N=3, Terminated, Sponsor: UCB, Inc.
There were no safety issues. N=50 --> 3
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, New P3 trial: Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis (clinicaltrials.gov) - Oct 11, 2011
P3, N=316, Active, not recruiting, Sponsor: Astellas Pharma Inc
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 27, 2011
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: RAPID-axSpA: Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (clinicaltrials.gov) - Aug 25, 2011
P3, N=325, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
N=50 --> 3 Recruiting --> Active, not recruiting